Oligonucleotides - The Official Journal of the Oligonucleotide Therapeutics Society (OTS)

Nucleic Acid Therapeutics The Official Journal of the Oligonucleotide Therapeutics Society (OTS) Published by Mary Ann Liebert Inc. www.liebertpub.com/oli The leading peer-reviewed journal that presents the latest research on oligonucleotide drug development
Audience	Academic and industry-based researchers, including all members of the Oligonucleotide Therapeutics Society
Frequency	10 issues per year
Editorial Focus	The Journal’s scope focuses not only on antisense oligonucleotides, but also on tracking advances in the development of ribozymes, immune stimulatory CpG oligos, and therapeutic RNAi. The only journal to focus solely on therapeutic oligonucleotides, while also covering: The full spectrum of oligonucleotide drug applications A broad view of oligonucleotide drug development The use of nucleic acids or related compounds to alter gene expression Synthetic oligonucleotides, including RNA, DNA, and ribozymes both in vitro and in vivo
Editor(s) in Chief	John J. Rossi, Ph.D. Department of Molecular Biology, Beckman Research Institute of the City of Hope, California C.A. Stein, M.D., Ph.D. Department of Oncology, Albert Einstein-Montefiore Cancer Center, Montefiore Medical Center, NY European Editor Prof. Dr. Jens Kurreck Universität Stuttgart, Institut für Industrielle Genetik
Print Advertising Options	Adverts, Inserts & Supplements
Digital Advertising Options	Banners on website Banners on subscriber Table of Contents email alerts
Further Information	Heleen Vodégel Tel: +44 (0) 1875 825 700 hvodegel@impressmedia.com
Publisher	Nucleic Acid Therapeutics is owned and published by Mary Ann Liebert, Inc. Editorial headquarters: 140 Huguenot Street, New Rochelle, New York 10801, USA. Phone: +1 (914) 740-2100. Fax: +1 (914) 740-2101 www.liebertpub.com

Nucleic Acid Therapeutics